Announcement PDF 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) LTR Pharma Executes Definitive U.S. Commercial Agreement with Strive Pharmacy 20 July 2026 Highlights  Definitive commercial agreement executed with Strive Specialties Inc, a leading U.S. Section 503A compounding pharmacy.  Converts the previously announced binding Term Sheet into a comprehensive long-form commercial agreement.  Establishes the manufacturing, compounding, fulfilment and national distribution framework for ROXUS® in the United States.  Completes the second key pillar of LTR Pharma’s U.S. commercialisation strategy alongside the previously announced Shed telehealth agreement.  Provides a scalable national manufacturing and fulfilment platform supporting telehealth, clinic and future commercial channels.  Represents another major milestone as the parties progress toward U.S. Commercial Launch. LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) has executed a definitive Compounding and Supply Agreement with Strive Specialties Inc. (“Strive Pharmacy”), converting the previously announced binding Term Sheet into a definitive long-form commercial agreement for the planned manufacture, compounding, fulfilment and nationwide supply of ROXUS® in the United States. The agreement establishes the commercial framework governing manufacturing, quality systems, API sourcing, product change control, fulfilment and supply-chain management as both companies prepare for Commercial Launch. Together with the recently executed definitive agreement with Shed, LTR Pharma now has in place the two core commercial pillars required for launch: patient acquisition and prescribing through telehealth, and national manufacturing and fulfilment through Strive Pharmacy. 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) Long-Term U.S. Manufacturing Partnership Strive Pharmacy operates an established Section 503A compounding platform across five U.S. states, with licensure supporting nationwide compounding, packaging, fulfilment and shipping of prescription treatments. Through this partnership, LTR Pharma gains access to an established national compounding pharmacy with the infrastructure, regulatory systems and fulfilment capability required to support Commercial Launch and future growth across its U.S. commercial channels. The agreement establishes the operational framework for technology transfer, manufacturing, quality systems, API procurement, inventory management and nationwide prescription fulfilment. Management believes the combination of Shed's patient acquisition capability and Strive Pharmacy’s manufacturing and fulfilment platform provides a scalable operational foundation for the U.S. commercialisation of ROXUS and supports the Company’s Commercial Launch strategy. Next Steps LTR Pharma and Strive Pharmacy will now focus on technology transfer, commercial inventory planning, manufacturing readiness and operational implementation ahead of Commercial Launch. The Company will continue to update shareholders as key Commercial Launch milestones are achieved. About Strive Pharmacy Strive Specialties Inc. (“Strive Pharmacy”) is a U.S.-based personalised medicine and Section 503A compounding pharmacy operating an established multi-state platform across five U.S. states, with licensure supporting nationwide compounding, packaging, fulfilment and shipping of prescription treatments. Strive Pharmacy supports prescribers, clinics and telehealth providers through its pharmacy fulfilment infrastructure and established clinic and provider network. Under the agreement, Strive Pharmacy is responsible for the preparation, fulfilment, shipping, and related quality and supply chain operations for ROXUS. 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) LTR Pharma Executive Chairman, Lee Rodne, said: “Executing the definitive agreement with Strive Pharmacy completes another major piece of our U.S. commercialisation strategy. While Shed provides patient acquisition and telehealth capability, Strive Pharmacy provides the national manufacturing, compounding and fulfilment infrastructure required to supply ROXUS across the United States. With both definitive agreements now in place, our focus shifts from partner selection to implementation and Commercial Launch. We believe this significantly strengthens our U.S. execution pathway and reduces commercial risk.” Strive Pharmacy President/Co-Founder, Michael Walker, said: “We are delighted to formalise our partnership with LTR Pharma. ROXUS is a highly differentiated product, and we look forward to supporting its U.S. launch through Strive Pharmacy’s national compounding, manufacturing and fulfilment capabilities.” - ENDS – This announcement has been approved by the Board of Directors. Forward-looking statement This announcement contains forward-looking statements, including in relation to the timing of Commercial Launch and the Company's commercial strategy. These statements are based on information currently available to the Company and involve known and unknown risks, uncertainties and assumptions, many of which are beyond the Company's control. Actual results may differ materially from those expressed or implied. The Company does not undertake to update any forward-looking statement except as required by law. About LTR Pharma LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the U.S. and other key markets. LTR’s lead products, SPONTAN® and ROXUS® , are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW® , a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function. Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life. 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) LTR Pharma Investor Centre Stay informed with LTR Pharma’s latest announcements and market updates by visiting our Investor Centre or scan the QR code. For further information please contact: Media enquiries Investor enquiries Haley Chartres Peter McLennan haley@hck.digital investors@ltrpharma.com